Clinical studies have shown that semi-synthetic homoharringtonine (sHHT) significantly reduces BCR-ABL transcript levels, particularly in Philadelphia chromosome-positive (Ph+) CML patients with poor response to imatinib, with excellent tolerability (169). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.